| 1 |
NCT02890212 |
Recruiting |
Selenium as Augmentation Treatment for Sertraline Resistant Major Depression |
|
- Dietary Supplement: selenium supplementation
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hamilton Depressive Rating Scale
- Montgomery-Asberg Depression Rating Scale
- Clinical Global Impression Scale
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02890212 |
Selen-2015 |
|
August 2005 |
December 2017 |
December 2017 |
September 7, 2016 |
May 3, 2017 |
|
- Instituto de Psiquiatria - Hcfmusp
São Paulo, Brazil
|
| 2 |
NCT00613912 |
Completed |
Advanced MRI in Major Depression |
- Depressive Disorder, Major
|
- Other: Magnetic Resonance Imaging
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Differences in morphological and functional cerebral MRI findings in patients suffering from major depression
|
49 |
All |
20 Years to 65 Years (Adult) |
NCT00613912 |
AUFF-2005-740-004 |
|
March 2008 |
December 2009 |
June 2011 |
February 13, 2008 |
November 21, 2011 |
|
- Aalborg Hospital / Aarhus University Hospital
Aalborg, Jutland, Denmark
|
| 3 |
NCT03060967 |
Not yet recruiting |
Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS) |
|
- Behavioral: Computer-based tasks
|
Interventional |
Not Applicable |
- Institut National de la Santé Et de la Recherche Médicale, France
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Screening
|
- Point of subjective equality (PSE)
- Percentage of subjective discrimination (PSD)
|
72 |
All |
18 Years to 60 Years (Adult) |
NCT03060967 |
C15-88 |
MOODDIS |
June 2017 |
September 2020 |
September 2020 |
February 23, 2017 |
May 12, 2017 |
|
|
| 4 |
NCT01768052 |
Unknown † |
Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression |
|
- Device: functional Near Infrared Spectroscopy
|
Observational |
|
- Mclean Hospital
- National Alliance for Research on Schizophrenia and Depression
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Change in the connectivity strength in the CCN as assessed by fMRI
- Change in brain activation in DLPFC as assessed by fNIRS monitoring
|
40 |
All |
21 Years to 45 Years (Adult) |
NCT01768052 |
2012P002394 |
|
June 2013 |
January 2016 |
January 2016 |
January 15, 2013 |
May 4, 2015 |
|
- McLean Hospital
Belmont, Massachusetts, United States - McLean Imaging Center/McLean TMS Service
Belmont, Massachusetts, United States
|
| 5 |
NCT02209142 |
Active, not recruiting |
Blood Biomarkers in Major Depression |
- Major Depressive Disorder
|
- Other: blood prelevement
- Other: psychometric data collection
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- describe a transcriptional signature of the Major Depressive Episode.
- evaluate the role played by confounding factors as genetic polymorphisms,
|
275 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02209142 |
2010-19 |
|
February 2012 |
November 2015 |
October 2016 |
August 5, 2014 |
July 27, 2016 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
| 6 |
NCT00286546 |
Completed |
Testosterone and Major Depression |
|
|
Observational |
|
- University Health Network, Toronto
|
Other |
- Observational Model: Defined Population
- Observational Model: Natural History
- Time Perspective: Cross-Sectional
- Time Perspective: Prospective
|
|
100 |
Male |
40 Years to 65 Years (Adult) |
NCT00286546 |
002 |
|
January 2001 |
|
August 2005 |
February 3, 2006 |
September 11, 2006 |
|
- Toronto Western Hospital
Toronto, Ontario, Canada
|
| 7 |
NCT00445237 |
Completed |
Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression |
|
- Device: H1 and H2 deep TMS coils
|
Interventional |
Phase 1 |
- Shalvata Mental Health Center
- Brainsway
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
|
All |
18 Years to 65 Years (Adult) |
NCT00445237 |
SH-505 |
|
May 2006 |
|
March 2008 |
March 8, 2007 |
February 5, 2009 |
|
- Shalvata MHC
Hod Hasharon, Israel
|
| 8 |
NCT01391221 |
Unknown † |
Inflammatory Markers and Cognitive Function in Major Depression |
|
|
Interventional |
Phase 4 |
- Centre de recherche Fernand-Seguin, Hôpital Louis-H. Lafontaine
- Eli Lilly and Company
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Cognitive function measured by CANTAB
- pain inhibition
- Allostatic load
|
20 |
All |
20 Years to 50 Years (Adult) |
NCT01391221 |
2011005 |
|
July 2011 |
August 2013 |
August 2013 |
July 11, 2011 |
July 19, 2012 |
|
- Centre de Recherche Fernand Seguin
Montreal, Quebec, Canada - Hôpital Maisonneuve Rosemont
Montreal, Quebec, Canada
|
| 9 |
NCT00208702 |
Completed |
Thyroid Medication and Antidepressants for Treating Major Depression |
|
- Drug: Triiodothyronine
- Other: Placebo
- Drug: Sertraline
|
Interventional |
Phase 4 |
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
153 |
All |
18 Years to 60 Years (Adult) |
NCT00208702 |
0431-1996
R01MH056946
431-1996
DSIR AT-SO |
|
September 1996 |
July 2003 |
July 2003 |
September 21, 2005 |
November 17, 2015 |
|
- Emory University
Atlanta, Georgia, United States
|
| 10 |
NCT00368303 |
Completed |
A Local Register Study For Major Depression Of Paroxetine Controlled Release |
- Depressive Disorder, Major
- Major Depressive Disorder (MDD)
|
- Drug: Paroxetine CR
- Drug: Paroxetine IR
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Scores on depression rating scale at treatment week 1,2,3,4,6 and 8.
- Scores on clinical impression severity and improvement items at treatment week 1, 2,3,4,6,8
|
362 |
All |
18 Years to 65 Years (Adult) |
NCT00368303 |
PCR103124 |
|
December 2006 |
|
|
August 24, 2006 |
June 4, 2012 |
|
- GSK Investigational Site
Guangzhou, Guangdong, China - GSK Investigational Site
Baoding, Hebei, China - GSK Investigational Site
Changsha, Hunan, China - (and 8 more...)
|
| 11 |
NCT03230682 |
Recruiting |
Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder |
- Major Depressive Disorder
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Early improvement
- Response
|
80 |
All |
16 Years to 55 Years (Child, Adult) |
NCT03230682 |
KY2017-01 |
|
July 25, 2017 |
June 11, 2018 |
July 11, 2018 |
July 26, 2017 |
July 26, 2017 |
|
- Dept. of Neurology, Huashan Hospital, Fudan University
Shanghai, Shanghai, China
|
| 12 |
NCT01182103 |
Completed
Has Results |
Epigenetic Regulation of BDNF in Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls
|
110 |
All |
18 Years to 60 Years (Adult) |
NCT01182103 |
NSC99-2628-B-182-002-MY2 |
|
August 2010 |
July 2012 |
May 2013 |
August 16, 2010 |
August 15, 2014 |
August 15, 2014 |
- Department of Psychiatry, Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
| 13 |
NCT00675896 |
Completed |
A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome |
|
- Drug: Quetiapine Fumarate Sustained Release
- Drug: Placebo
|
Interventional |
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- last observation carried forward (LOCF) mean change from baseline to week 8 on the Hamilton Depression Scale (HAM-D) total score.
- Change from baseline to week 8 in: Brief Pain Inventory,HAM-A,CGI-S,FIQ, Sleep Scale from the Medical Outcome Study,SDS,QLES- Short Form,PHQ-15,Global Assessment Scale,Improvement (CGI-I) score from randomisation to Week 8
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT00675896 |
D1443C00007 |
|
April 2007 |
June 2011 |
July 2011 |
May 12, 2008 |
July 6, 2011 |
|
- Dr. A McIntyre Inc
Penticton, British Columbia, Canada
|
| 14 |
NCT01625546 |
Completed |
Whole Body Hyperthermia and Major Depression (MDD) |
- Depressive Disorder, Major
|
- Device: Whole Body Hyperthermia system
|
Interventional |
Not Applicable |
- University of Arizona
- Dr. med. h.c. Erwin Braun Foundation
- The Depressive and Bipolar Disorder Alternative Treatment Foundation
- Brain & Behavior Research Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- 17-item Hamilton Rating Scale for Depression (HAM-D; derived from the 31-item instrument)
- Change in QIDS (Quick Inventory of Depressive Symptoms) Score from baseline response
- Core body temperature monitoring
- (and 6 more...)
|
34 |
All |
18 Years to 65 Years (Adult) |
NCT01625546 |
12-0147-01 |
|
July 2012 |
May 2015 |
May 2015 |
June 21, 2012 |
August 10, 2015 |
|
- University of Arizona
Tucson, Arizona, United States
|
| 15 |
NCT00705185 |
Completed |
Exploring a Potential Blood Test to Diagnose Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- Precision Human Biolaboratories
- Cambridge Health Alliance
- (and 3 more...)
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
- 16 Biological Markers; Group comparison between adults with Major Depressive Disorder and healthy controls
|
120 |
All |
18 Years to 65 Years (Adult) |
NCT00705185 |
2007-P-002525 |
Bio-TestMDD |
April 2008 |
June 2010 |
June 2010 |
June 25, 2008 |
June 8, 2010 |
|
- University of Connecticut Health Center
Farmington, Connecticut, United States - Psychiatric Medicine Associates, L.L.C.
Chicago, Illinois, United States - Massachusetts General Hosptial
Boston, Massachusetts, United States - (and 2 more...)
|
| 16 |
NCT01734291 |
Completed |
Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression |
- Major Depressive Disorder
|
- Behavioral: Family psychoeducation
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The change of total score of K6 of family members
- The change of total score of Family Attitude Scale(FAS) of family members
|
49 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT01734291 |
NCUPsychiatricNursing001
ID24593499 |
|
October 1, 2012 |
June 20, 2016 |
October 9, 2016 |
November 27, 2012 |
April 5, 2017 |
|
- Fujika Katsuki
Nagoya, Aichi, Japan
|
| 17 |
NCT00159146 |
Terminated |
Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression |
|
- Drug: Pindolol and venlafaxin
|
Interventional |
Not Applicable |
- Hillerod Hospital, Denmark
- Wyeth is now a wholly owned subsidiary of Pfizer
- Tvergaards Foundation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Hamilton Depression Rating Scale scores
- Preskorn scores
|
31 |
All |
18 Years and older (Adult, Senior) |
NCT00159146 |
version 5 |
|
August 2002 |
|
September 2007 |
September 12, 2005 |
December 27, 2007 |
|
- Psychiatric Research Unit, Hillerod Hospital
Hillerod, Denmark
|
| 18 |
NCT00149071 |
Completed |
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression |
|
|
Interventional |
Not Applicable |
- Hillerod Hospital, Denmark
- Medicon Valley Academy
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
|
61 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00149071 |
1,2 |
|
March 2004 |
|
January 2006 |
September 8, 2005 |
November 5, 2007 |
|
- Psychiatric research unit, Hilleroed Hospital,
Hillerod, Denmark
|
| 19 |
NCT02165449 |
Recruiting |
Biomarkers of Fast Acting Therapies in Major Depression |
- Major Depressive Disorder
|
|
Interventional |
Phase 1 |
- University of California, Los Angeles
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Hamilton Depression Rating Scale measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- Change in the Hamilton Depression Rating Scale measured between the last ketamine infusion treatment and 5 week follow-up
- Change in gene expression measured between baseline and 24 hrs following the first ketamine infusion treatment, and 24 hrs following up to three additional ketamine infusions
- (and 7 more...)
|
60 |
All |
18 Years to 64 Years (Adult) |
NCT02165449 |
HS001796
K24MH102743
U01MH110008 |
|
June 2014 |
August 2020 |
August 2021 |
June 17, 2014 |
February 13, 2018 |
|
- Geffen School of Medicine, UCLA
Los Angeles, California, United States
|
| 20 |
NCT00220623 |
Unknown † |
Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression |
|
- Drug: antidepressant medications, flexible drug choice
- Behavioral: CBT, Psychodynamic or Supportive Psychotherapy
|
Interventional |
Phase 3 |
- Sir Mortimer B. Davis - Jewish General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Time to recovery of major depressive episode
- Time to recurrence of major depression, once recovered
- improvement in depressive defenses
- (and 3 more...)
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT00220623 |
#04-013 |
|
August 2004 |
|
|
September 22, 2005 |
September 22, 2005 |
|
- Institute of Community and Family Psychiatry
Montreal, Quebec, Canada
|
| 21 |
NCT01579942 |
Terminated |
Potential Use Of Brain Network Activation Analysis to Diagnose Major Depression |
- Major Depressive Disorder
|
|
Observational |
|
- Massachusetts General Hospital
- ElMindA Ltd
|
Other / Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Brain Network Analysis group patterns
- Identify possible predictors of treatment response
|
70 |
All |
18 Years to 55 Years (Adult) |
NCT01579942 |
2011P000200 |
|
April 2012 |
|
|
April 18, 2012 |
March 6, 2017 |
|
- Depression Clinical and Research Program
Boston, Massachusetts, United States
|
| 22 |
NCT00472576 |
Completed
Has Results |
Antidepressant Effects of NR2B in Major Depression |
|
- Drug: MK-0657
- Drug: Placebo
|
Interventional |
Phase 1 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MADRS)
- Hamilton Depression Rating Scale (HDRS)
|
5 |
All |
18 Years to 55 Years (Adult) |
NCT00472576 |
070152
07-M-0152 |
|
May 2007 |
August 2009 |
August 2009 |
May 11, 2007 |
August 3, 2012 |
April 7, 2011 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 23 |
NCT00419003 |
Completed
Has Results |
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications |
|
- Drug: Lamotrigine
- Drug: Ketamine
- Drug: Riluzole
|
Interventional |
Phase 4 |
- Baylor College of Medicine
- National Alliance for Research on Schizophrenia and Depression
- National Center for Research Resources (NCRR)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Montgomery-Asberg Depression Rating Scale (MARDS) Score (Acute Response to IV Ketamine in Patients With Treatment Resistant Major Depression)
- Efficacy of Lamotrigine in Decreasing IV Ketamine Psychotomimetic Side Effects
|
26 |
All |
21 Years to 70 Years (Adult, Senior) |
NCT00419003 |
05-0850
5M01RR000071-46 |
|
December 2006 |
July 2008 |
September 2008 |
January 5, 2007 |
March 21, 2016 |
March 21, 2016 |
- Mount Sinai School of Medicine
New York, New York, United States
|
| 24 |
NCT00208156 |
Completed |
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression |
- Depressive Disorder, Major
|
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-07
- To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated
|
87 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00208156 |
C-1073-10 |
|
May 2005 |
November 2006 |
November 2006 |
September 21, 2005 |
February 15, 2012 |
|
- Cnri, Llc
San Diego, California, United States - Atlanta Center for Medical Research
Atlanta, Georgia, United States - Robert Horne M.D.
Las Vegas, Nevada, United States - (and 10 more...)
|
| 25 |
NCT00427128 |
Completed |
Prozac Treatment of Major Depression: Discontinuation Study |
|
- Drug: fluoxetine
- Drug: placebo
|
Interventional |
Phase 4 |
- New York State Psychiatric Institute
- Massachusetts General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MDD section of Mood Disorders Module of Structured Clinical Interview for DSM-IV (SCID)
- Ham-D
- CGI
|
627 |
All |
18 Years to 65 Years (Adult) |
NCT00427128 |
4099R
RO1 MH56058 |
|
November 1995 |
|
March 2003 |
January 26, 2007 |
December 15, 2011 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - New York State Psychiatric Institute
New York, New York, United States
|
| 26 |
NCT03347487 |
Recruiting |
Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression |
- Treatment Resistant Major Depression Disorder
|
- Procedure: Surgical Intervention
- Device: Shame DBS device followed by active DBS
- Device: Active DBS device followde by shame DBS
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- changes in the Hamilton Depression Scale(HAMD-17)
- changes in the Montgomery-Asberg Depression Rating Scale
- changes in the brain activity
- (and 4 more...)
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT03347487 |
Habenula |
|
November 13, 2017 |
November 30, 2018 |
November 30, 2018 |
November 20, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
| 27 |
NCT01418638 |
Unknown † |
The Metabolic Effects of Antidepressants in Patients Diagnosed With Major Depressive Disorder |
- Major Depressive Disorder
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- the influence of antidepressant medications on the metabolic profiles (5) of patients suffering from Major Depressive Disorder.
|
30 |
All |
18 Years to 65 Years (Adult) |
NCT01418638 |
01-11 ZIV |
|
May 2012 |
October 2013 |
|
August 17, 2011 |
February 20, 2013 |
|
|
| 28 |
NCT00229645 |
Completed |
A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety |
- Major Depression With Comorbid Anxiety Symptoms
|
- Drug: Quetiapine Fumarate (Seroquel®)
|
Interventional |
Phase 4 |
- Dr Alexander McIntyre Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To compare the efficacy of quetiapine versus placebo over 8 weeks as an adjunctive agent for unipolar non-psychotic adult outpatients on SSRI or SNRI therapy with residual symptoms of depression and comorbid anxiety symptoms. This will be measured by the
- 1. Hamilton Depression Scale (HAM-D) total score,
- 2. Hamilton Anxiety Scale (HAM-A) total score
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT00229645 |
D1441C00017 |
|
November 2003 |
|
April 2005 |
September 30, 2005 |
July 13, 2016 |
|
- Dr. A. McIntyre
Penticton, British Columbia, Canada
|
| 29 |
NCT00714779 |
Completed |
Fluoxetine vs. Brief Psychotherapy for Major Depression |
- Major Depressive Disorder
|
- Drug: Fluoxetine
- Behavioral: Short-term psychodynamic psychotherapy
|
Interventional |
Not Applicable |
- University of Turku
- KELA
- Finnish State Grant
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
85 |
All |
20 Years to 60 Years (Adult) |
NCT00714779 |
HK123 |
|
January 2000 |
December 2004 |
December 2004 |
July 14, 2008 |
July 14, 2008 |
|
|
| 30 |
NCT00944996 |
Completed |
Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression |
|
|
Interventional |
Not Applicable |
- Tirat Carmel Mental Health Center
- University of Michigan
- Ariel University
- The Nazareth Hospital, Israel
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Measurements of PACAP and BDNF serum levels
- Analysis of genetic variants of PACAP and PAC1 coding and regulatory regions
|
100 |
All |
18 Years to 65 Years (Adult) |
NCT00944996 |
akparl08
920080174
040-2008 |
|
June 2009 |
June 2010 |
July 2012 |
July 23, 2009 |
July 26, 2012 |
|
- Tirat Carmel Mental Health Center
Tirat Hacarmel, Israel
|
| 31 |
NCT01824433 |
Completed |
Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression |
|
- Drug: venlafaxine
- Drug: fluoxetine
|
Interventional |
Phase 4 |
- Capital Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall Improvement
- Improvement of individual symptoms
|
189 |
Female |
50 Years to 80 Years (Adult, Senior) |
NCT01824433 |
VFPWMDD |
|
March 7, 2013 |
March 16, 2017 |
March 16, 2017 |
April 4, 2013 |
September 14, 2017 |
|
- Beijing Anding Hospital
Beijing, Beijing, China
|
| 32 |
NCT03254017 |
Recruiting |
Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial |
- Treatment Resistant Major Depressive Disorder
|
- Procedure: Bilateral surgical implantation of DBS system to Habeluna
- Other: Follow-up Period
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the Montgomery-Asberg Depression Rating Scale
- Change in the Hamilton Depression Scale
- Change in the Hamilton Anxiety Scale
- (and 5 more...)
|
6 |
All |
18 Years to 65 Years (Adult) |
NCT03254017 |
Habenula DBS |
|
July 24, 2017 |
July 30, 2018 |
August 30, 2019 |
August 18, 2017 |
March 2, 2018 |
|
- Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China - Shanghai Ruijin Hospital Functional Neurosurgery
Shanghai, Shanghai, China
|
| 33 |
NCT03295708 |
Recruiting |
Fish Oil as Adjunct Treatment for Major Depressive Disorder |
- Major Depressive Disorder
|
- Dietary Supplement: fish oil capsule
- Dietary Supplement: soybean oil capsule
|
Interventional |
Not Applicable |
- Second Xiangya Hospital of Central South University
- Xiangya Hospital of Central South University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in Hamilton Depression Scale (HAMD) HAMD
- Changes in Clinical Global Impression (CGI)
- Changes in Hamilton Anxiety Scale (HAMA)
- (and 2 more...)
|
120 |
All |
18 Years to 50 Years (Adult) |
NCT03295708 |
MDD201610 |
|
October 1, 2017 |
October 1, 2019 |
April 1, 2020 |
September 28, 2017 |
October 10, 2017 |
|
- Mental Health Institute, Second Xiangya Hospital of Central South University
Changsha, Hunan, China
|
| 34 |
NCT01450150 |
Not yet recruiting |
Transcranial Direct Current Stimulation as an Augmenting Intervention for Major Depression |
- Major Depressive Disorder
|
- Device: Transcranial Direct Current Stimulation
|
Interventional |
Phase 2
Phase 3 |
- Douglas Mental Health University Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C)
- 21-item Hamilton Depression Rating Scale (HAM-D21)
- Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR)
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT01450150 |
tDCS-ERB08/04-2011 |
|
January 2016 |
October 2018 |
October 2018 |
October 12, 2011 |
January 20, 2016 |
|
- Douglas Mental Health University Institute
Montreal, Quebec, Canada
|
| 35 |
NCT00489775 |
Completed |
Duloxetine Versus Paroxetine for Major Depression |
- Major Depressive Disorder
|
- Drug: Duloxetine
- Drug: Paroxetine
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To assess hypothesis that efficacy of duloxetine 60mg QD is non-inferior to paroxetine 20mg QD in treating major depressive disorder as defined by DSM-IV. Primary efficacy evaluated by mean change of HAMD17 total scores from baseline to endpoint.
- To compare the efficacy of duloxetine 60 mg QD and paroxetine 20 mg QD on anxiety symptoms associated with depression as measured by mean changes in Hamilton Anxiety Rating Scale (HAMA) total scores
- To compare efficacy of treatment with duloxetine 60 mg QD and paroxetine 20 mg QD on symptoms of depression measured by mean endpoint scale on the Clinical Global Impression of Severity Scale (CGI-S) scale and the endpoint score
- (and 4 more...)
|
480 |
All |
18 Years and older (Adult, Senior) |
NCT00489775 |
6937
F1J-AA-HMCV |
|
January 2004 |
|
June 2005 |
June 21, 2007 |
June 21, 2007 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beijing, China
|
| 36 |
NCT00510822 |
Completed |
Cimicoxib for the Treatment of Major Depression (SECIM) |
|
- Drug: Cimicoxib
- Drug: Placebo
|
Interventional |
Phase 2 |
- Affectis Pharmaceuticals AG
- FGK Clinical Research GmbH
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- • Mean change on the total score of the Hamilton Depression Rating Scale (HamD-17) from baseline to endpoint (Week 6).
- • Changes from baseline to interim weekly visits (week 1 to 5) in HamD-17 score • Clinical Global Impression (CGI) score • Montgomery Asberg Depression Rating Scale (MADRS) score • Response rate, remission rate and drop out rate. • Onset of
|
169 |
All |
18 Years to 60 Years (Adult) |
NCT00510822 |
AFX-01
EudraCT-No. 2007-001335-54 |
|
October 2007 |
February 2010 |
February 2010 |
August 2, 2007 |
November 13, 2013 |
|
- Landeskrankenhaus Klagenfurt, Abteilung für Psychiatrie und Psychotherapie
Klagenfurt, Austria - Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria - Faculty Hospital Brno
Brno, Czech Republic - (and 22 more...)
|
| 37 |
NCT01944657 |
Withdrawn |
Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study |
- 1. Major Depressive Disorder
|
- Device: Supplemental TMS
- Drug: Standard Medication Monotherapy
|
Interventional |
Not Applicable |
- Sheppard Pratt Health System
- Central Michigan University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Montgomery-Åsberg Depression Rating Scale (MADRS)
- Hamilton Rating Scale for Depression (HRSD)
|
0 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01944657 |
SPHS IRB [354612-3] |
|
September 2013 |
December 2015 |
December 2015 |
September 18, 2013 |
April 25, 2017 |
|
- Sheppard Pratt Health System
Towson, Maryland, United States
|
| 38 |
NCT01741142 |
Terminated |
Efficacy and Safety Study of ABT-436 in Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: ABT-436
- Drug: Escitalopram
- Drug: Placebo
|
Interventional |
Phase 2 |
- AbbVie (prior sponsor, Abbott)
- AbbVie
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.
- Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.
|
19 |
All |
18 Years to 65 Years (Adult) |
NCT01741142 |
M11-733 |
|
January 2012 |
October 2013 |
August 2015 |
December 4, 2012 |
October 8, 2013 |
|
- Site Reference ID/Investigator# 85593
Little Rock, Arkansas, United States - Site Reference ID/Investigator# 87228
Garden Grove, California, United States - Site Reference ID/Investigator# 87214
National City, California, United States - (and 15 more...)
|
| 39 |
NCT00125554 |
Completed |
Metyrapone as Additive Treatment in Major Depression |
- Major Depressive Disorder
|
|
Interventional |
Phase 2 |
- Universitätsklinikum Hamburg-Eppendorf
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Two psychometric criteria defined by the number of responders and time to onset-of-action. The number of responders was considered twice after 3 and 5 weeks by defining the treatment response as a 30% and 50% reduction
- the course of concentrations of ACTH, cortisol, 11-deoxycortisol and DHEA.
- Other psychometric scores, demographic parameters and side effects were considered as secondary variables.
|
63 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00125554 |
HH-PSY-ja-007 |
|
May 1998 |
|
July 2001 |
August 1, 2005 |
August 12, 2005 |
|
- Dept. of Psychiatry and Psychotherapy, UKE
Hamburg, Germany
|
| 40 |
NCT02484456 |
Recruiting |
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder |
|
- Drug: AV 101 (4-Chlorokynurenine)
- Other: Placebo
|
Interventional |
Phase 2 |
- National Institute of Mental Health (NIMH)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in the Hamilton Depression Rating scale total score.
- Change from baseline in BPRS, CADSS, C-SSRS, HAM-A, HDRS, MADRS, PANAS, SHAPS, SSI, TEPS, YMRS total scores.
- Change from baseline in the C-SSRS total score.
- (and 3 more...)
|
25 |
All |
18 Years to 65 Years (Adult) |
NCT02484456 |
150151
15-M-0151 |
|
June 19, 2015 |
December 31, 2019 |
December 31, 2019 |
June 29, 2015 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 41 |
NCT03012724 |
Recruiting |
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) |
- Major Depressive Disorder (MDD)
|
- Device: H7-Coil
- Device: H1-Coil
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HDRS-21 Score Change From Baseline
- Response Rate in HDRS-21
- Remission Rate
|
106 |
All |
22 Years to 68 Years (Adult, Senior) |
NCT03012724 |
CTP-0001-01 |
|
March 30, 2017 |
January 2019 |
April 2019 |
January 6, 2017 |
April 10, 2018 |
|
- Kadima Neuropsychiatry
La Jolla, California, United States - Advanced Mental Health Care Inc. - Juno Beach
Juno Beach, Florida, United States - Advanced Mental Health Care Inc. - Palm Beach
Palm Beach, Florida, United States - (and 5 more...)
|
| 42 |
NCT02489305 |
Recruiting |
Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD) |
- Depressive Disorder, Major
|
|
Observational |
|
- Janssen Research & Development, LLC
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Participants With Near Term Relapse
|
330 |
All |
18 Years to 64 Years (Adult) |
NCT02489305 |
CR105160
OBSERVEMDD0001 |
|
December 15, 2014 |
April 30, 2018 |
May 1, 2018 |
July 3, 2015 |
January 12, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Behavioral Research Specialists
Glendale, California, United States - North County Clinical Research
Oceanside, California, United States - (and 25 more...)
|
| 43 |
NCT02793258 |
Recruiting |
Impact of tDCS on Emotional Processing in Major Depression |
- Major Depressive Disorder
|
- Device: transcranial direct current stimulation
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of correct responses at a facial expression recognition task
- Evolution of the depressive symptoms measured by MADRS
- Performance on an attentional dot-probe task
- (and 7 more...)
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT02793258 |
2016-A00415-46 |
EmoStim |
July 22, 2016 |
June 2018 |
September 2018 |
June 8, 2016 |
July 11, 2017 |
|
- Ch Le Vinatier
Lyon, Rhone Alpes, France
|
| 44 |
NCT00531947 |
Completed
Has Results |
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression |
- Major Depressive Disorder
|
- Drug: Selegiline Transdermal System
- Drug: Placebo
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12
- CGI-S - Week 12 (mITT w/LOCF Population)
- CGI-C - Week 12 (mITT w/LOCF Population)
- (and 16 more...)
|
308 |
All |
12 Years to 17 Years (Child) |
NCT00531947 |
S9303-P0605 |
|
July 2007 |
October 2010 |
October 2010 |
September 19, 2007 |
January 15, 2014 |
June 26, 2013 |
- Dr. Nelson Handal
Dothan, Alabama, United States - Dr. Mohammed Bari
National City, California, United States - Dr. Michael McManus
SanDiego, California, United States - (and 17 more...)
|
| 45 |
NCT01685294 |
Completed |
Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression |
- Major Depressive Disorder
|
- Behavioral: Group IPT for Depression + TAU
|
Interventional |
Phase 3 |
- Brown University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline in Hamilton Rating Scale for Depression (HRSD) at 3 Months
- Change from Baseline in Suicidality at 3 Months
- Change from Baseline in In-Prison Functioning at 3 Months
- (and 4 more...)
|
181 |
All |
18 Years and older (Adult, Senior) |
NCT01685294 |
1R01MH095230-01
R01MH095230 |
|
December 2011 |
October 2014 |
October 2014 |
September 14, 2012 |
January 13, 2016 |
|
- Massachusetts Correctional Institute - Old Colony Correctional Center
Bridgewater, Massachusetts, United States - Massachusetts Correctional Institution - Framingham
Framingham, Massachusetts, United States - South Middlesex Correctional Center
Framingham, Massachusetts, United States - (and 2 more...)
|
| 46 |
NCT00461279 |
Completed |
Attachment Security as Mediator and Moderator of Outcome in Major Depression |
|
- Behavioral: Cognitive Behavior Therapy
- Behavioral: Interpersonal Psychotherapy
|
Interventional |
Not Applicable |
- Centre for Addiction and Mental Health
- Ontario Mental Health Foundation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT00461279 |
165/2006 |
|
August 2006 |
February 2010 |
March 2010 |
April 17, 2007 |
December 6, 2011 |
|
- Centre for Addiction and Mental Health
Toronto, Ontario, Canada
|
| 47 |
NCT01838876 |
Completed |
To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) |
- Major Depressive Disorder
|
|
Interventional |
Phase 3 |
- Forest Laboratories
- Gedeon Richter Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and Tolerability in patients with Major Depressive Disorder (assessments w ill include adverse events, clinical laboratory parameters, vital signs, Electrocardiograms, Extra Pyramidal Symptom (EPS) scales, and ophthalmologic examination)
|
442 |
All |
18 Years to 65 Years (Adult) |
NCT01838876 |
RGH-MD-76 |
|
April 29, 2013 |
July 27, 2015 |
July 27, 2015 |
April 24, 2013 |
March 12, 2018 |
|
- Forest Investigative Site 032
Tucson, Arizona, United States - Forest Investigative Site 109
Tucson, Arizona, United States - Forest Investigative Site 105
Fayetteville, Arkansas, United States - (and 87 more...)
|
| 48 |
NCT00351169 |
Completed |
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder |
- Major Depressive Disorder
|
- Drug: Quetiapine SR
- Drug: Escitalopram
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To evaluate the efficacy of quetiapine SR compared with placebo in the treatment of patients with major depressive disorder (MDD) as assessed by change from randomisation to week 8 score in the MADRS total score.
- If quetiapine SR improves health-related quality of life of patients with MDD, compared to placebo
|
450 |
All |
18 Years to 65 Years (Adult) |
NCT00351169 |
D1448C00004
AMBER
EUDRACT No: 2005-005052-40 |
AMBER |
May 2006 |
|
June 2007 |
July 12, 2006 |
December 22, 2008 |
|
- Research Site
Edmonton, Alberta, Canada - Research Site
Kelowna, British Columbia, Canada - Research Site
Penticton, British Columbia, Canada - (and 39 more...)
|
| 49 |
NCT01426997 |
Completed |
Phenotype Depression Study |
- Major Depressive Disorder
|
|
Observational |
|
- Emory University
- National Institute of Mental Health (NIMH)
|
Other / NIH |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
- We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.
|
279 |
All |
21 Years to 65 Years (Adult) |
NCT01426997 |
IRB00039107
1R01MH087604-01A1 |
|
July 2010 |
May 2016 |
May 2016 |
September 1, 2011 |
June 22, 2016 |
|
- Emory University Department of Psychiatry and Behavioral Sciences
Atlanta, Georgia, United States
|
| 50 |
NCT00289484 |
Unknown † |
A Study of Omega-3 as an Augmentor of Antidepressant Treatment for Major Depression |
|
- Drug: Omega-3 Polyunsaturated Fatty Acids
|
Interventional |
Phase 2 |
- The University of New South Wales
- Your Health Inc.
- Sphere Healthcare
- Ocean Nutrition
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change form pretreatment score on Depression Rating scale at 4 weeks
- Daily mood rating
- Weekly measure of depression
- (and 2 more...)
|
52 |
All |
18 Years to 65 Years (Adult) |
NCT00289484 |
05156 |
|
February 2006 |
|
|
February 9, 2006 |
September 13, 2006 |
|
- The University of New South Wales/Black Dog Institute
Sydney, New South Wales, Australia
|
Create an RSS feed from your search for:
Download the search results for: